Compare Moderna, Inc. (MRNA) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs VICI Properties Inc — how do they compare? Moderna, Inc. trades at $197.5 (market cap $78.65B), while VICI Properties Inc trades at $22.89 (market cap $25.09B). The key difference: Moderna, Inc. is far larger — about 3.1× VICI Properties Inc's market cap, and VICI Properties Inc pays a 8.07% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and VICI Properties Inc for 42 Days on average.
| MRNA | VICI | |
|---|---|---|
Market Cap | $78.65B | $25.09B |
Volume | 37,373,437 | 17,066,337 |
Sector | Health | Real Estate |
52-Week High | $203.46 | $31.42 |
52-Week Low | $22.36 | $22.53 |
Typical Hold Time | 59 Days | 42 Days |
Enterprise Value | $74.80B | $42.65B |
Dividend Yield | — | 8.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
VICI Properties trades at $22.64, down 0.4% on the day, with a bearish technical outlook despite strong fundamentals. The REIT maintains exceptional profitability with 67.5% net margins and trades at attractive valuations (P/E 8.83, P/B 0.86). Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing, while the company continues expanding its tenant base through new lease agreements.
Wall Street remains bullish with 75% buy ratings and a $28.90 consensus target, representing 28% upside. Key risks include tenant concentration and rising interest rates, but the 7.8% dividend yield appears well-covered by strong cash flows. The current discount to NAV presents a compelling opportunity for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
